1. Home
  2. EIGR

EIGR

Eiger BioPharmaceuticals Inc.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-18-2024 3:58pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
-
.
-
-
%

Eiger BioPharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.

Founded: N/A Country:
United States
United States
Employees: N/A City: PALO ALTO
Market Cap: 3.1M IPO Year: N/A
Target Price: $120.00 AVG Volume (30 days): 113.7K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -50.78 EPS Growth: N/A
52 Week Low/High: $1.10 - $43.35 Next Earning Date: 05-09-2024
Revenue: $15,773,000 Revenue Growth: 16.98%
Revenue Growth (this year): 39.19% Revenue Growth (next year): 37.05%

Share on Social Networks: